Zembrace Symtouch(Sumatriptan Succinate)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$2.5M
Medicare cost, 2024
$2.5M
Medicare cost, 2024
Medicare drug plans spent $2.5 million on Zembrace Symtouch (sumatriptan succinate) in 2024, for 1,408 prescriptions and refills filled by 342 patients. California accounts for the most spending ($347,165, 14% of the total).
Medicare cost, 2024
$2.5M
-14.9% from 2023
Prescriptions
1,408
$1,784.79 per claim
Patients
342
353 prescribers
Total spending, 2024
$2.5M
$7,347.89 per patient
Questions and answers
How much does Medicare spend on Zembrace Symtouch?
Medicare prescription drug plans paid $2.5M for Zembrace Symtouch in 2024, for 1,408 prescriptions and refills to 342 patients (down 14.9% from 2023). The average cost per claim was $1,784.79.
Which state spends the most on Zembrace Symtouch?
California had the highest Medicare cost for Zembrace Symtouch in 2024: $347K for 162 claims, followed by New York ($240K).
Who prescribes Zembrace Symtouch the most?
Michael A Giglio, neurology in Williamsville, NY, had the highest Medicare cost for Zembrace Symtouch in 2024: 15 claims costing $80K.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Zembrace Symtouch was $2.5M in 2024, after a high of $3.0M in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Zembrace Symtouch, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Michael A Giglio Williamsville, NY | Neurology | 15 | Under 11 | $80K |
| Jack D Schim Carlsbad, CA | Neurology | 27 | Under 11 | $40K |
| Trenton P Timmer Hickory, NC | Physician Assistant | 24 | Under 11 | $38K |
| Paul G Mathew Cambridge, MA | Neurology | 17 | Under 11 | $38K |
| Christopher P O'Carroll Newport Beach, CA | Neurology | 16 | Under 11 | $35K |
| Jamie L Brisendine Philadelphia, PA | Physician Assistant | 11 | Under 11 | $33K |
| Leslie A Masood Downers Grove, IL | Neurology | 12 | Under 11 | $30K |
| Lorenzo O Aguilar Jr. Modesto, CA | Neurology | 15 | Under 11 | $26K |
| Harry L McDaris Jr. Huntsville, AL | Neurology | 21 | Under 11 | $23K |
| Nawaf H Murshed Taylor, MI | Neurology | 12 | Under 11 | $22K |
| Violeta Avramov Toms River, NJ | Neurology | 13 | Under 11 | $19K |
| Qahtan A Abdulfattah Brooksville, FL | Neurology | 12 | Under 11 | $19K |
| Shamin Masrour Dallas, TX | Neurology | 12 | Under 11 | $18K |
| Cynthia K McGarvey Indianapolis, IN | Neurology | 12 | Under 11 | $18K |
| Josepha Simi La Jolla, CA | Physician Assistant | 12 | Under 11 | $18K |
| Nicole Rothman Durham, NC | Nurse Practitioner | 11 | Under 11 | $17K |
| Ashley Olsin Dallas, TX | Family Practice | 13 | Under 11 | $16K |
| Amandeep Pal Lockport, NY | Family Practice | 15 | Under 11 | $12K |
| Mary Hoffman Merrillville, IN | Nurse Practitioner | 14 | Under 11 | $11K |
| Donna M Dundon Scottsdale, AZ | Nurse Practitioner | 13 | Under 11 | $10K |
| Lynn Rankin Des Moines, IA | Psychiatry | 13 | Under 11 | $9,732 |
| Jennifer V Robblee Phoenix, AZ | Neurology | 13 | Under 11 | $9,436 |
| Sharon K Jung Tacoma, WA | Nurse Practitioner | 11 | Under 11 | $8,900 |
| Joshua A Maksi Hattiesburg, MS | Neurology | 11 | Under 11 | $8,747 |
| Kristina P Cassmeyer Lexington, KY | Nurse Practitioner | 11 | Under 11 | $8,610 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 371 | 1,671 | 388 | $2.8M |
| 2023 | 362 | 1,618 | 363 | $3.0M |
| 2024 | 353 | 1,408 | 342 | $2.5M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Up-Sm/Tonix Pha | 1,391 | $2.5M |
| Promius/Upsher- | 17 | $23K |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 3
- RxNorm concept IDs
- 1738576, 1738581
- Application numbers
- NDA208223
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 46,818 side-effect reports named sumatriptan succinate, the active ingredient of Zembrace Symtouch (reports from 1996 on). 23,105 of them (49.4%) were serious, 1,146 named a death and 8,607 named a hospital stay. The reactions named most often were drug ineffective, headache and nausea. 12,788 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
46,818
2,450 in 2025 (-3.2% from 2024)
Serious
49.4%
23,105 reports
Deaths named
1,146
2.4% of reports
Hospital stays
8,607
18.4% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
Since 2002. 2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Zembrace Symtouch?
46,818 reports from 1996 through September 2026 named sumatriptan succinate, the active ingredient of Zembrace Symtouch. 23,105 of them (49.4%) were serious, 1,146 named a death and 8,607 named a hospital stay.
What are the most reported side effects of Zembrace Symtouch?
6,582 reports named drug ineffective, the reaction named most often, followed by headache (3,967) and nausea (3,542). In the last 5 years the reaction named most often was drug ineffective (1,545 reports). A report can name several reactions.
How many side-effect reports named Zembrace Symtouch in 2025?
2,450 reports were received in 2025 (-3.2% from 2024). 2026 so far: 2,273 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Zembrace Symtouch caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Zembrace Symtouch caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with sumatriptan succinate: Sumatriptan Succinate, Imitrex, Onzetra Xsail, Imitrex*, Sumatriptan Succinate*
- Makers on the stock market:
GSK·GSK drug pipeline - Drug approvals (10 approvals on file for sumatriptan succinate) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (sumatriptan succinate) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.